# Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

> **NCT00003268** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University**

## Conditions studied

- Drug/Agent Toxicity by Tissue/Organ
- Leukemia

## Interventions

- **DRUG:** amifostine trihydrate
- **DRUG:** cytarabine
- **DRUG:** idarubicin

## Key facts

- **NCT ID:** NCT00003268
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-01
- **Primary completion:** —
- **Final completion:** 2003-12
- **Target enrollment:** — (—)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003268, "Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT00003268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*